|
Peripheral Arterial Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haplotype analysis using the 2 variants (rs2735940 and rs2853669) showed that subjects with the at-risk C-C haplotype had shorter telomere length than those individuals with the T-T haplotype and consistently had 1.30-fold (OR 1.30, 95%CI 1.06-1.58; P=0.005) increased risk for PAD.
|
23082138 |
2012 |
|
Carcinoma of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
In the logistic regression analysis, TERT-rs2853669, rs2736108, and CLPTM1L-rs31490 were significant associated with increased risk of lung cancer (OR = 1.46, 95% CI = 1.22-1.75; OR = 1.22, 95% CI = 1.00-1.49 and OR = 1.74, 95% CI = 1.35-2.23 under additive model, respectively).
|
23908149 |
2013 |
|
Malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
In the logistic regression analysis, TERT-rs2853669, rs2736108, and CLPTM1L-rs31490 were significant associated with increased risk of lung cancer (OR = 1.46, 95% CI = 1.22-1.75; OR = 1.22, 95% CI = 1.00-1.49 and OR = 1.74, 95% CI = 1.35-2.23 under additive model, respectively).
|
23908149 |
2013 |
|
Primary malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
In the logistic regression analysis, TERT-rs2853669, rs2736108, and CLPTM1L-rs31490 were significant associated with increased risk of lung cancer (OR = 1.46, 95% CI = 1.22-1.75; OR = 1.22, 95% CI = 1.00-1.49 and OR = 1.74, 95% CI = 1.35-2.23 under additive model, respectively).
|
23908149 |
2013 |
|
Recurrent tumor
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data showed that a common polymorphism rs2853669, within a preexisting Ets2 binding site in the TERT promoter, acts as a modifier of the effect of the mutations on survival and tumor recurrence.
|
24101484 |
2013 |
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
The TERT core promoter region containing the previously described mutations and a common functional polymorphism (rs2853669) was sequenced in tumors and blood samples from 192 GBM patients.
|
25140036 |
2015 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
We observed an association of allele rs2853669 C with increased risk of prostate cancer (co-dominant model TC vs. TT OR = 1.65, P = 0.002; additive model OR = 1.42, P = 0.005; dominant model: OR = 1.64, P = 0.001) and allele rs7726159 A with reduced risk of this malignancy (сo-dominant model: AA vs. CC OR = 0.42, P = 0.002; additive model: OR = 0.69, P = 0.002; dominant model: OR = 0.67, P = 0.01; recessive model: OR = 0.48, P = 0.005).
|
25296732 |
2015 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
We observed an association of allele rs2853669 C with increased risk of prostate cancer (co-dominant model TC vs. TT OR = 1.65, P = 0.002; additive model OR = 1.42, P = 0.005; dominant model: OR = 1.64, P = 0.001) and allele rs7726159 A with reduced risk of this malignancy (сo-dominant model: AA vs. CC OR = 0.42, P = 0.002; additive model: OR = 0.69, P = 0.002; dominant model: OR = 0.67, P = 0.01; recessive model: OR = 0.48, P = 0.005).
|
25296732 |
2015 |
|
Malignant neoplasm of prostate
|
|
0.010 |
GeneticVariation
|
BEFREE |
We observed an association of allele rs2853669 C with increased risk of prostate cancer (co-dominant model TC vs. TT OR = 1.65, P = 0.002; additive model OR = 1.42, P = 0.005; dominant model: OR = 1.64, P = 0.001) and allele rs7726159 A with reduced risk of this malignancy (сo-dominant model: AA vs. CC OR = 0.42, P = 0.002; additive model: OR = 0.69, P = 0.002; dominant model: OR = 0.67, P = 0.01; recessive model: OR = 0.48, P = 0.005).
|
25296732 |
2015 |
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We observed an association of allele rs2853669 C with increased risk of prostate cancer (co-dominant model TC vs. TT OR = 1.65, P = 0.002; additive model OR = 1.42, P = 0.005; dominant model: OR = 1.64, P = 0.001) and allele rs7726159 A with reduced risk of this malignancy (сo-dominant model: AA vs. CC OR = 0.42, P = 0.002; additive model: OR = 0.69, P = 0.002; dominant model: OR = 0.67, P = 0.01; recessive model: OR = 0.48, P = 0.005).
|
25296732 |
2015 |
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
TERT rs2853669 polymorphism was found in 44.4% of tumors.
|
25448848 |
2015 |
|
Glioblastoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
|
25681309 |
2015 |
|
Glioblastoma Multiforme
|
|
0.010 |
GeneticVariation
|
BEFREE |
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
|
25681309 |
2015 |
|
Childhood Glioblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
|
25681309 |
2015 |
|
Adult Glioblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
|
25681309 |
2015 |
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Interleukin-6 (IL-6) expression regulated by TERT promoter status and polymorphism, what leads us to think that TERT and IL-6 plays a significant role in GBM, where specific SNPs increase the risk of developing GBM while the rs2853669 SNP and specific mutations in the TERT promoter of the tumor lead to shorter survival.
|
26143636 |
2015 |
|
Acute monocytic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show that rs2853669 CC may be a risk factor for the development of AML that may also be used as a prognostic marker to identify high risk normal karyotype-AML (NK-AML) patients, for treatment guidance.
|
26298771 |
2015 |
|
Leukemia, Myelocytic, Acute
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show that rs2853669 CC may be a risk factor for the development of AML that may also be used as a prognostic marker to identify high risk normal karyotype-AML (NK-AML) patients, for treatment guidance.
|
26298771 |
2015 |
|
Sarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our aim is to determine the frequency of c.-124 C>T and c.-146 C>T TERT mutations and to genotype the rs2853669 polymorphism in a series of 68 soft tissue sarcomas (STS) comprising 22 histological subtypes.
|
26391479 |
2016 |
|
Steroid Sulfatase Deficiency Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
The variant C allele of rs2853669 was found in 54.8% (34/62) of all STSs and in 75% (3/4) of TERT-mutated cases.
|
26391479 |
2016 |
|
Sarcoma of soft tissue
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our aim is to determine the frequency of c.-124 C>T and c.-146 C>T TERT mutations and to genotype the rs2853669 polymorphism in a series of 68 soft tissue sarcomas (STS) comprising 22 histological subtypes.
|
26391479 |
2016 |
|
Ichthyosis, X-Linked
|
|
0.010 |
GeneticVariation
|
BEFREE |
The variant C allele of rs2853669 was found in 54.8% (34/62) of all STSs and in 75% (3/4) of TERT-mutated cases.
|
26391479 |
2016 |
|
Malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
The effect of rs2853669 on lung cancer</span> risk was significant in younger individuals (OR=1.73, 95% CI=1.18-2.54, P=0.005) and adenocarcinoma (OR=1.50, 95% CI=1.07-2.07, P=0.02).
|
26425038 |
2015 |
|
Primary malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
The effect of rs2853669 on lung cancer</span> risk was significant in younger individuals (OR=1.73, 95% CI=1.18-2.54, P=0.005) and adenocarcinoma (OR=1.50, 95% CI=1.07-2.07, P=0.02).
|
26425038 |
2015 |
|
Carcinoma of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
The effect of rs2853669 on lung cancer</span> risk was significant in younger individuals (OR=1.73, 95% CI=1.18-2.54, P=0.005) and adenocarcinoma (OR=1.50, 95% CI=1.07-2.07, P=0.02).
|
26425038 |
2015 |